The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
Open accessAbstract
Purpose: Combining cisplatin or cetuximab with radiation improves overall survival (OS) of patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum regimens also increase OS in metastatic HNC. The Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetuximab to the radiation-cisplatin platform improves progression-free survival (PFS). Patients and Methods: Eligible patients with stage III or IV HNC were randomly assigned to receive radiation and cisplatin without (arm A) or with (arm B) cetuximab. Acute and late reactions were scored using Common Terminology Criteria for Adverse Events (version 3). Outcomes were correlated with patient and tumor features and markers. Results: Of 891 analyzed patients, 630 were alive at analysis (median follow-up, 3.8 years). Cetuximab plus cisplatin-radiation, versus cisplatin-radiation alone, resulted in more frequent interruptions in radiation therapy (26.9% v 15.1%, respectively); similar cisplatin delivery (mean, 185.7 mg/m 2 v 191.1 mg/m 2, respectively); and more grade 3 to 4 radiation mucositis (43.2% v 33.3%, respectively), rash, fatigue, anorexia, and hypokalemia, but not more late toxicity. No differences were found between arms A and B in 30-day mortality (1.8% v 2.0%, respectively; P = .81), 3-year PFS (61.2% v 58.9%, respectively; P = .76), 3-year OS (72.9% v 75.8%, respectively; P = .32), locoregional failure (19.9% v 25.9%, respectively; P = .97), or distant metastasis (13.0% v 9.7%, respectively; P = .08). Patients with p16-positive oropharyngeal carcinoma (OPC), compared with patients with p16-negative OPC, had better 3-year probability of PFS (72.8% v 49.2%, respectively; P < .001) and OS (85.6% v 60.1%, respectively; P < .001), but tumor epidermal growth factor receptor (EGFR) expression did not distinguish outcome. Conclusion: Adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely. PFS and OS were higher in patients with p16-positive OPC, but outcomes did not differ by EGFR expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566
Self-citationRadiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Self-citationPlatinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Machtay, M., Moughan, J., Trotti, A., Garden, A. S., Weber, R. S., Cooper, J. S., Forastiere, A., & Ang, K. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8841 · Cited by 1,371
Self-citationFu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., & Ang, K. K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00663-5 · Cited by 1,357
Self-citationThe Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Fully conditional specification in multivariate imputation
Van Buuren, S., Brand, J. P. L., Groothuis-Oudshoorn, C. G. M., & Rubin, D. B. (2006) · Journal of Statistical Computation and Simulation · doi:10.1080/10629360600810434 · Cited by 1,217
Ang, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R. L., Hammond, E. H., Fu, K. K., & Milas, L. (2002) · PubMed · Cited by 1,198
Self-citationBurtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Huang, S., Bock, J. M., & Harari, P. M. (1999) · PubMed · Cited by 714
Overgaard, J., Hansen, H. S., Specht, L., Overgaard, M., Grau, C., Andersen, E., Bentzen, J., Bastholt, L., Hansen, O., Johansen, J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14361-9 · Cited by 685
The randomization and stratification of patients to clinical trials
Zelen, M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90015-0 · Cited by 613
Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
Milas, L., Mason, K. A., Hunter, N. R., et al. (2000) · PubMed · Cited by 503
Fan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Grandis, J. R., Melhem, M. F., Barnes, E. L., & Tweardy, D. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960915)78:6<1284::aid-cncr17>3.0.co;2-x · Cited by 369
Begum, S., Gillison, M. L., Ansari-Lari, M. A., Shah, K. V., & Westra, W. H. (2003) · PubMed · Cited by 307
Self-citationPfister, D. G., Su, Y. B., Kraus, D. H., Wolden, S. L., Lis, E., Aliff, T. B., Zahalsky, A. J., Lake, S., Needle, M. N., Shaha, A. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1792 · Cited by 297
Psyrri, A., Yu, Z., Weinberger, P. M., Sasaki, C., Haffty, B., Camp, R., Rimm, D., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 269
Ang, K. K., & Sturgis, E. M. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.12.004 · Cited by 260
Self-citationMichiels, S., Le Maître, A., Buyse, M., Burzykowski, T., Maillard, E., Bogaerts, J., Vermorken, J. B., Budach, W., Pajak, T. F., Ang, K. K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70023-3 · Cited by 170
Self-citationSaleh, M. N., Raisch, K. P., Stackhouse, M. A., et al. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.451 · Cited by 154
Sensitivity Analysis When Data Are Missing Not-at-random
Resseguier, N., Giorgi, R., & Paolettí, X. (2011) · Epidemiology · doi:10.1097/ede.0b013e318209dec7 · Cited by 69
Chung, C. H., Zhang, Q., Hammond, E. M., Trotti, A., Wang, H., Spencer, S. A., Zhang, H.-Z., Cooper, J. S., Jordan, R. C., Rotman, M., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.024 · Cited by 57
Self-citationNakata, E., Hunter, N. R., Mason, K. A., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.02.050 · Cited by 49
Cited by
Chow, L. Q. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1715715 · Cited by 2,075
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0031 · Cited by 1,360
Self-citationGillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., Jordan, R. C. K., Zhao, W., Sturgis, E. M., Burtness, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32779-x · Cited by 1,304
Self-citationForastiere, A. A., Zhang, Q., Weber, R. S., Maor, M. H., Goepfert, H., Pajak, T. F., Morrison, W., Glisson, B., Trotti, A., Ridge, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.6097 · Cited by 1,296
Self-citationHead and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.12.017 · Cited by 1,174
Metadata
- Authors
- Ang, K. K., Zhang, Q., Rosenthal, D. I., Nguyen-Tan, P. F., Sherman, E. J., Weber, R. S., Galvin, J. M., Bonner, J. A., Harris, J., El-Naggar, A. K., Gillison, M. L., Jordan, R. C., Konski, A. A., Thorstad, W. L., Trotti, A., Beitler, J. J., Garden, A. S., Spanos, W. J., Yom, S. S., & Axelrod, R. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-09-20
- Volume
- 32
- Issue
- 27
- Pages
- 2940-2950
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146488048
- Cited by
- 838
- References
- 33
- FWCI
- 83.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.